Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic of Cardamine violifolia

ABSTRACT: Proteomic of Cardamine violifolia treated by sodium selenate

ORGANISM(S): Cardamine Circaeoides

SUBMITTER: Feng Xu

PROVIDER: PXD016541 | iProX | Mon Dec 02 00:00:00 GMT 2019

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Transcriptome, proteome, and metabolome reveal the mechanism of tolerance to selenate toxicity in Cardamine violifolia.

Rao Shen S Yu Tian T Cong Xin X Lai Xiaozhuo X Xiang Jiqian J Cao Jie J Liao Xiaoli X Gou Yuanyuan Y Chao Wei W Xue Hua H Cheng Shuiyuan S Xu Feng F

Journal of hazardous materials 20201022

Cardamine violifolia was found here to accumulate selenium (Se) to over 9000 mg kg<sup>-1</sup> dry weight. To investigate the mechanism of Se accumulation and tolerance in C. violifolia, metabolome, transcriptome, and proteome technologies were applied to C. violifolia seedlings treated with selenate. Several sulfate transporter (Sultr) genes (Sultr1;1, Sultr1;2, and Sultr2;1) and sulfur assimilatory enzyme genes showed high expression levels in response to selenate. Many calcium protein and cy ...[more]

PMID: 33187796

Similar Datasets

Alterations to the Hidradenitis Suppurativa Serum Proteome with Spleen Tyrosine Kinase Antagonism: Proteomic Results from a Phase 2 Clinical Trial.

Project description:Serum Proteomic Analysis of patients with Hidradenitis Suppurativa treated with Fostamatinib

2023-08-10 | GSE240607 | GEO

Proteomic

Project description:Proteomic

2022-12-31 | OEX00021177 | NODE

Secretome of Bone Marrow Stroma-Derived Neural Progenitor Cells: Proteomic Analysis

Project description:We found the bone marrow stromal-derived neural progenitor cells secretome have the neural protection effect. Proteomic analysis was performed nn order to analyze the protection factor in the secretome. Keywords: Neural protection, secretome

2008-10-18 | GSE13242 | GEO

PDEEV proteomic

Project description:PDEEV proteomic

2022-01-14 | OEX00015730 | NODE

Proteomic Comparison Of DSRCT, Normal Mesenteric Tissues and ES

Project description:Desmoplastic small round cell tumor (DSRCT) is an aggressive malignancy that occurs predominantly in young adult males and is characterized by abdominopelvic sarcomatosis exhibiting multi-lineage cellular nests of epithelial, muscular, mesenchymal, and neural differentiation admixed with desmoplastic stroma. Prior to the recognition of the disease as a distinct clinical entity, DSRCT was invariably misclassified as poorly differentiated atypical cancer of the testes, ovary, mesentery, or gastrointestinal tract, and the chemotherapies used for those malignancies elicited poor clinical response. As previously reported, a tectonic shift in the treatment of these patients occurred after researchers made two astute observations: 1) DSRCT microscopically resembles other small round “blue cell” sarcoma subtypes (e.g., ES, rhabdomyosarcoma, synovial sarcoma), and 2) DSRCT and ES have the same N-terminal EWSR1 fusion partner. Proteomic analysis using a reverse-phase protein lysate array (RPPA) was used to elucidate biomarkers that distinguish DSRCT from adjacent normal tissue and Ewing sarcoma. This proteomic analysis revealed novel proteins, such as the androgen receptor and Syk, that may be susceptible to drug targeting, as well as oncogenic pathways like Akt-PI3K that are highly expressed in DSRCT.

2020-12-31 | GSE108687 | GEO

Identification of an effective early signaling signature during neo-vasculogenesis in vivo by ex vivo proteomic profiling

Project description:Therapeutic neo-vasculogenesis in vivo can be achieved by the co-transplantation of human endothelial colony-forming progenitor cells (ECFCs) with mesenchymal stem/progenitor cells (MSPCs).The underlying mechanism is not completely understood thus hampering the development of novel stem cell therapies.We hypothesized that proteomic profiling could be used to retrieve the in vivo signaling signature during the initial phase of human neo-vasculogenesis. ECFCs and MSPCs were therefore either transplanted alone or co-transplanted subcutaneously into immune deficient mice. Early cell signaling, occurring within the first 24 hours in vivo, was analyzed using antibody microarray proteomic profiling.Vessel formation and persistence were verified in parallel transplants for up to 24 weeks. Proteomic analysis revealed significant alteration of regulatory components including caspases, calcium/calmodulin-dependent protein kinase, DNA protein kinase,human ErbB2 receptor-tyrosine kinase as well as mitogen-activated protein kinases.Therapeutic candidate caspase-4 was selected from array results for targeting vascular network formation in vitro as well as modulating therapeutic vasculogenesis in vivo. As a proof-of-principle, caspase-4 and general caspase-blocking led to diminished endothelial network formation in vitro and significantly decreased vasculogenesis in vivo. Proteomic profiling ex vivo thus unraveled a signaling signature which can be targeted to modulate neo-vasculogenesis in vivo.

2013-04-09 | GSE45896 | GEO

Rapid Attenuation of B-Cell and Interferon Gamma Associated Chemokines in Clinical Responders to Janus Kinase Inhibition with Upadacitinib in Hidradenitis Suppurativa II.

Project description:Serum Proteomic Analysis of patients with Pyoderma Gangrenosum Treated with Tildrakizumab 200mg q4weekly for 12 weeks

2023-08-18 | GSE241085 | GEO

Characteristic molecular and proteomic signatures of drug-induced liver injury in a rat model

Project description:we assessed characteristic molecular and proteomic signatures in rat liver treated with drugs (pyrazinamide, ranitidine, enalapril, carbamazepine, and chlorpromazine) that are known to cause DILI in humans.

2013-08-16 | GSE49631 | GEO

Rapid Attenuation of B-Cell and Interferon Gamma Associated Chemokines in Clinical Responders to Janus Kinase Inhibition with Upadacitinib in Hidradenitis Suppurativa.

Project description:Serum Proteomic Analysis of patients with Hidradenitis Suppurativa treated with 15mg daily of Upadacitinib. Samples from Week 0 and Week 4 of therapy, Straficied by clinical response.

2023-06-18 | GSE235140 | GEO